Evidence map›Paper›PMID 36851694›Full record

ArticleViruses2023

Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.

Larisa V Kordyukova, Andrey V Moiseenko, Marina V Serebryakova, Marina A Shuklina, Maria V Sergeeva, Dmitry A Lioznov, Andrei V Shanko

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Larisa V KordyukovaBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-6089-1103
Andrey V MoiseenkoFaculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.
Marina V SerebryakovaBelozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.
Marina A ShuklinaWHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia.ORCID 0000-0002-7550-5519
Maria V SergeevaWHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia.ORCID 0000-0003-0411-9896
Dmitry A LioznovWHO National Influenza Center, Smorodintsev Research Institute of Influenza, 197376 Saint-Petersburg, Russia.
Andrei V ShankoR&D Department, FORT LLC, 119435 Moscow, Russia.ORCID 0000-0001-9801-9911
Lomonosov Moscow State University · RUResearch Institute of Influenza · RUBaikov Institute of Metallurgy and Materials Science · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inactivated vaccines are promising tools for tackling the COVID-19 pandemic. We applied several protocols for SARS-CoV-2 inactivation (by β-propiolactone, formaldehyde, and UV radiation) and examined the morphology of viral spikes, protein composition of the preparations, and their immunoreactivity in ELISA using two panels of sera collected from convalescents and people vaccinated by Sputnik V. Transmission electron microscopy (TEM) allowed us to distinguish wider flail-like spikes (supposedly the S-protein's pre-fusion conformation) from narrower needle-like ones (the post-fusion state). While the flails were present in all preparations studied, the needles were highly abundant in the β-propiolactone-inactivated samples only. Structural proteins S, N, and M of SARS-CoV-2 were detected via mass spectrometry. Formaldehyde and UV-inactivated samples demonstrated the highest affinity/immunoreactivity against the convalescent sera, while β-propiolactone (1:2000, 36 h) and UV-inactivated ones were more active against the sera of people vaccinated with Sputnik V. A higher concentration of β-propiolactone (1:1000, 2 h) led to a loss of antigenic affinity for both serum panels. Thus, although we did not analyze native SARS-CoV-2 for biosafety reasons, our comparative approach helped to exclude some destructive inactivation conditions and select suitable variants for future animal research. We believe that TEM is a valuable tool for inactivated COVID-19 vaccine quality control during the downstream manufacturing process.

Indexed as

COVID-19Spike Glycoprotein, CoronavirusAnimalsCOVID-19 SerotherapyCOVID-19 VaccinesFormaldehydeHumansPandemicsPropiolactoneSARS-CoV-2Vaccines, InactivatedCOVID-19 VaccinesFormaldehydePropiolactoneSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, InactivatedELISAformaldehydeimmunoreactivityMALDI-TOF mass spectrometrypost-fusionpre-fusionSARS-CoV-2 inactivationS proteintransmission electron microscopyUV irradiationβ-propiolactone

Identifiers

PMID36851694
PMCPMC9961907
OpenAlexW4319759104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.